- Home
- IMMX vs CRT Comparison
IMMX vs CRT Comparison
Compare IMMX & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- CRT
- Stock Information
- Founded
- IMMX 2014
- CRT 1991
- Country
- IMMX United States
- CRT United States
- Employees
- IMMX N/A
- CRT N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- CRT Oil & Gas Production
- Sector
- IMMX Health Care
- CRT Energy
- Exchange
- IMMX Nasdaq
- CRT Nasdaq
- Market Cap
- IMMX 65.5M
- CRT 65.1M
- IPO Year
- IMMX 2021
- CRT 1992
- Fundamental
- Price
- IMMX $2.00
- CRT $7.72
- Analyst Decision
- IMMX Strong Buy
- CRT
- Analyst Count
- IMMX 1
- CRT 0
- Target Price
- IMMX $8.00
- CRT N/A
- AVG Volume (30 Days)
- IMMX 183.0K
- CRT 24.5K
- Earning Date
- IMMX 11-11-2025
- CRT 01-01-0001
- Dividend Yield
- IMMX N/A
- CRT 11.57%
- EPS Growth
- IMMX N/A
- CRT N/A
- EPS
- IMMX N/A
- CRT 0.92
- Revenue
- IMMX N/A
- CRT $6,559,820.00
- Revenue This Year
- IMMX N/A
- CRT N/A
- Revenue Next Year
- IMMX N/A
- CRT N/A
- P/E Ratio
- IMMX N/A
- CRT $8.38
- Revenue Growth
- IMMX N/A
- CRT N/A
- 52 Week Low
- IMMX $1.26
- CRT $7.67
- 52 Week High
- IMMX $3.20
- CRT $13.31
- Technical
- Relative Strength Index (RSI)
- IMMX 48.92
- CRT 17.34
- Support Level
- IMMX N/A
- CRT $8.46
- Resistance Level
- IMMX $2.34
- CRT $8.79
- Average True Range (ATR)
- IMMX 0.15
- CRT 0.17
- MACD
- IMMX -0.08
- CRT -0.08
- Stochastic Oscillator
- IMMX 85.11
- CRT 4.39
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.